Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9.

Abstract

Despite initial responses to hormone treatment, metastatic prostate cancer invariably evolves to a lethal state. To characterize the intra-patient evolutionary relationships of metastases that evade treatment, we perform genome-wide copy number profiling and bespoke approaches targeting the androgen receptor (AR) on 167 metastatic regions from 11 organs harvested post-mortem from 10 men who died from prostate cancer. We identify diverse and patient-unique alterations clustering around the AR in metastases from every patient with evidence of independent acquisition of related genomic changes within an individual and, in some patients, the co-existence of AR-neutral clones. Using the genomic boundaries of pan-autosome copy number changes, we confirm a common clone of origin across metastases and diagnostic biopsies, and identified in individual patients, clusters of metastases occupied by dominant clones with diverged autosomal copy number alterations. These autosome-defined clusters are characterized by cluster-specific AR gene architectures, and in two index cases are topologically more congruent than by chance (p-values 3.07 × 10-8 and 6.4 × 10-4). Integration with anatomical sites suggests patterns of spread and points of genomic divergence. Here, we show that copy number boundaries identify treatment-selected clones with putatively distinct lethal trajectories.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clone Cells / pathology
  • DNA Copy Number Variations*
  • Genome
  • Genomics
  • Humans
  • Male
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / pathology
  • Receptors, Androgen / genetics

Substances

  • Receptors, Androgen